Literature DB >> 7758053

Methods of cost-effectiveness analysis: areas of consensus and debate.

B R Luce1, K Simpson.   

Abstract

Methods of evaluating socioeconomic relationships have evolved over many years, and a number of specific approaches have been developed. Among the techniques available, cost-effectiveness analysis (CEA) has emerged as the most widely used and accepted method. Yet, despite considerable effort by the analytical community to refine this technique into one more useful for making health policy decisions, much debate and confusion still persist among analysts, readers, and policy-makers concerning methods standards and the overall usefulness of CEA in resource allocation decision making. Thus the purpose of this paper is to summarize, critically examine, and comment on existing recommended methods for socioeconomic evaluation of health care interventions. In particular, we examine an exhaustive set of component methods within the general area of cost-effectiveness and comment on areas of apparent consensus and debate. Our review reveals many areas of agreement and many yet to be resolved. Analysts generally agree on the components of the overall framework for an analysis; basic methodologic principles; the general treatment of costs; the principle of marginal analysis; the need for and general approach to discounting; the use of sensitivity analysis; the extent to which ethical issues can be incorporated; and the importance of choosing appropriate alternatives for comparison. The principal areas in which disagreement still persists are choice of study design, measurement and valuation of health outcomes including conversion of health outcomes to economic values, transformation of efficacy results into effectiveness outcomes, and the empirical measurement of costs.

Mesh:

Year:  1995        PMID: 7758053     DOI: 10.1016/0149-2918(95)80012-3

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

1.  Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Authors:  M Iskedjian; K Trakas; C A Bradley; A Addis; K Lanctôt; D Kruk; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 2.  The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

Authors:  C Donaldson
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 3.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

4.  Decision analysis for the cost-effective management of recurrent colorectal cancer.

Authors:  K C Park; J Schwimmer; J E Shepherd; M E Phelps; J R Czernin; C Schiepers; S S Gambhir
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  Cost effectiveness of a community based research project to help women quit smoking.

Authors:  R H Secker-Walker; R R Holland; C M Lloyd; D Pelkey; B S Flynn
Journal:  Tob Control       Date:  2005-02       Impact factor: 7.552

6.  Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.

Authors:  Carlos Crespo; Antonio Monleon; Walter Díaz; Martín Ríos
Journal:  BMC Med Res Methodol       Date:  2014-12-22       Impact factor: 4.615

7.  The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios.

Authors:  Elinor C G Chumney; Andrea K Biddle; Kit N Simpson; Morris Weinberger; Kathryn M Magruder; William N Zelman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Breast scintigraphy today: indications and limitations.

Authors:  Orazio Schillaci; John R Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.